News
-
-
COMMUNIQUÉ DE PRESSE
Nextech3D.AI Announces Increase in Revenue Growth for ARway Following Map D Acquisition
Nextech3D.AI reports a +194% increase in unaudited revenue and 5% gross margin growth for ARway post-Map Dynamics acquisition. Strong financial performance drives Nextech3D.AI's commitment to innovation -
COMMUNIQUÉ DE PRESSE
Silver Spruce Appoints Paul K. Smith and William Fleming to Company’s Advisory Board
Silver Spruce Resources Inc. appoints Paul K. Smith and William Fleming to Advisory Board. Smith brings mineral deposits expertise, Fleming offers strategic foresight and corporate governance. Company explores new projects in Canada, Mexico, and the USA -
COMMUNIQUÉ DE PRESSE
ARway.ai Announces Substantial Increase in Revenue Growth Following Map D Acquisition
ARway reports robust +194% increase in unaudited revenue and 5% gross margin growth post Map Dynamics acquisition. Nextech3D.AI renews share purchase warrant program to reward workforce and align interests with company's success -
COMMUNIQUÉ DE PRESSE
Gungnir Receives Swedish Gold Line Permit Approvals and Announces Collaboration with LTU for Ni-Cu-PGE Study
Gungnir Resources Inc. obtains final approval for permit applications within Knaften-Hemberget gold project in Sweden. Collaboration with LTU for high-grade nickel deposit study -
COMMUNIQUÉ DE PRESSE
EV Nickel Drills Best Hole to Date & Expands Nickel Sulphide Zone at Gemini North Intersecting 186.5m Grading 0.36% Nickel
EV Nickel Inc. announces successful results from diamond drill program at the Gemini North Zone on Shaw Dome Project. The program reveals high-grade nickel mineralization, enrichened sulphur contents, and potential for a magmatic sulphide source -
COMMUNIQUÉ DE PRESSE
UniDoc Announces Purchase Agreement for AGNES Connect Software from AMD Telemedicine
UniDoc Health Corp. announces strategic acquisition of AGNES Connect software from AMD Telemedicine, enhancing eHealth capabilities. Acquisition to accelerate software platform expansion, strengthen telehealth offering, and increase shareholder value -
-
-
COMMUNIQUÉ DE PRESSE
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Xenetic Biosciences reports encouraging preclinical data on DNase-based technology targeting NETosis for difficult cancers. Focus on clinical studies partnerships and DNase I development program for pancreatic carcinoma
